Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBT (2020 - 2025)

Historic EBT for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$34.0 million.

  • Lyell Immunopharma's EBT rose 2369.33% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 7161.37%. This contributed to the annual value of -$334.7 million for FY2024, which is 4971.13% down from last year.
  • As of Q3 2025, Lyell Immunopharma's EBT stood at -$34.0 million, which was up 2369.33% from -$43.9 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's EBT registered a high of -$11.3 million during Q4 2022, and its lowest value of -$196.2 million during Q4 2024.
  • Moreover, its 5-year median value for EBT was -$52.4 million (2023), whereas its average is -$57.0 million.
  • In the last 5 years, Lyell Immunopharma's EBT surged by 7600.13% in 2022 and then plummeted by 36266.0% in 2023.
  • Over the past 5 years, Lyell Immunopharma's EBT (Quarter) stood at -$47.2 million in 2021, then skyrocketed by 76.0% to -$11.3 million in 2022, then tumbled by 362.66% to -$52.4 million in 2023, then tumbled by 274.31% to -$196.2 million in 2024, then soared by 82.68% to -$34.0 million in 2025.
  • Its last three reported values are -$34.0 million in Q3 2025, -$43.9 million for Q2 2025, and -$53.5 million during Q1 2025.